Trial Profile
A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Nov 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 21 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.
- 01 Oct 2021 Results published in the Breast Cancer Research and Treatment